Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 15/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL31651561 | 0.91 | MTNR1A (0.36) | LRRK2MTNR1AMTNR1BFPR2PROKR1 | |
| SCHEMBL31411485 | 0.90 | LRRK2 (0.37) | HTR1ALRRK2MTNR1AMTNR1BHTR2B | |
| SCHEMBL31411448 | 0.85 | HTR1A (0.40) | HTR1ALRRK2LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL31651554 | 0.85 | HTR1A (0.42) | HTR1ALRRK2HSD17B10HTR2B | |
| Fumaric Acid SCHEMBL31411289 | 0.81 | ESR1 (0.37) | LRRK2MTNR1AMTNR1BLMNARAB9A | |
| SCHEMBL31411469 | 0.81 | MTNR1A (0.34) | HTR1ALRRK2MTNR1AMTNR1BFPR2 | |
| SCHEMBL31411298 | 0.79 | HRH3 (0.38) | HTR1ALRRK2MTNR1AMTNR1B | |
| Fumaric Acid SCHEMBL31411274 | 0.77 | ACHE (0.37) | HTR1ALRRK2MTNR1AMTNR1BLMNA | |
| SCHEMBL31411445 | 0.76 | HTR1A (0.42) | HTR1ALRRK2MTNR1AMTNR1BLMNA | |
| SCHEMBL31411338 | 0.74 | HTR1A (0.59) | HTR1AMTNR1AMTNR1BLMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | HTR1A 185/4885LRRK2 1294/4885MTNR1A 888/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | HTR1A 185/4885LRRK2 1294/4885MTNR1A 888/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | HTR1A 185/4885LRRK2 1294/4885MTNR1A 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.